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Several studies have evaluated the efficacy of using human oncolytic adenovirus-loaded 
mesenchymal stem cells for cancer treatment. For example, we have described the antitumor 
efficacy of CELYVIR, autologous bone marrow mesenchymal stem cells infected with the 
oncolytic adenovirus ICOVIR-5, for treatment of neuroblastoma patients. Results from this 
clinical trial point out the role of the immune system in the clinical outcome. In this context, a 
better understanding of the immunophenotypic changes of human mesenchymal stem cells upon 
adenoviral infection and how these changes affect human autologous or allogeneic peripheral 
blood mononuclear cells (PBMCs) could guide strategies to improve the antitumor efficacy of 
infected Mesenchymal Stem Cells (MSCs). In this work, we show how infection by an oncolytic 
adenovirus (OAdv) induces Toll-like receptor 9 overexpression and activation of the NF-B 
pathway in menstrual blood-derived mesenchymal stem cells (MenSCs), leading to a specific 
cytokine secretion profile. Moreover, a pro-inflammatory environment, mainly mediated by 
monocyte activation that leads to the activation of both T-cells and natural killer cells (NK cells), 
is generated when OAdv-loaded MenSCs are co-cultured with allogeneic PBMCs. This 
combination of allogeneic PBMCs and OAdv-loaded MenSCs enhances antitumor efficacy both 
in vitro and in vivo, an effect partially mediated monocytes and NK cells. Altogether our results 
demonstrate not only the importance of the immune system for the oncolytic adenovirus-loaded 









Among the variety of strategies designed to improve the limited antitumor efficacy observed 
after systemic oncolytic adenovirus (OAdv) administration in clinical trials, the use of 
mesenchymal stem cells (MSCs) as cell carriers for oncolytic adenovirus is of special interest 
because of their natural tumor tropism (1) and immunomodulatory properties (2). In the last 
decades, we and others have studied the use of MSCs as cell carriers for oncolytic adenoviruses. 
In this context, CELYVIR, a therapeutic approach exploiting the use of autologous human bone 
marrow-derived MSCs as cell carriers for the oncolytic adenovirus ICOVIR5, has been evaluated 
in clinical studies for pediatric refractory metastatic neuroblastoma treatment (NTC01844661). 
Results from this clinical trial demonstrated tolerance to the treatment and clinical responses 
including complete remissions (3,4). The activation status of the immune system of the patients 
and the inflammatory profile of the MSCs were suggested to play a role in treatment outcome 
(4). Recently, a dog version of CELYVIR consisting in the combination of dog healthy 
allogeneic MSCs infected with a canine oncolytic adenovirus has been evaluated in a clinical 
study to treat spontaneous canine tumor (5). A 74% response rate was determined in the assay 
with 14.8% showing complete responses, including total remissions of lung metastasis. 
Interestingly, microenvironment alterations and immune cell infiltration in tumor after treatment 
were observed. Altogether, these clinical data pointed out the main role of the immune system 
for OAdv-loaded MSCs antitumor efficacy although more experimental evidences are needed to 
better understand the immune mechanisms involved in the antitumor efficacy of CELYVIR. 
The immunosuppressive properties of mesenchymal stem cells have been extensively reported 
(2,6,7). However, in 2010, the group of Aline Betancourt introduced a new paradigm for MSCs: 
their polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype 
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(8,9), with a clear impact on tumor growth (10). More recently it has been reviewed how 
pathogen-associated molecular patterns (PAMPS) modulate MSCs immunophenotype by 
signaling through Toll-like Receptors (TLRs), including the activation of TLR-3 by poly(I:C), 
TLR-4 by Lipopolysaccharide (LPS) or TLR-9 by non-methylated CpG sequence (11,12). 
Recognition of unmethylated CpG motifs from adenovirus double-stranded DNA by dendritic 
cells’ TLR-9 leads to their maturation and induces transcriptional activation of pro-inflammatory 
cytokines and inflammasome components (13). Thus, although it has not been demonstrated for 
human mesenchymal stem cells, it is plausible to hypothesize that adenoviral infection could 
switch the immune-phenotype of MSCs toward a pro-inflammatory status through the activation 
of TLR-9. 
Systemic administration of OAdv-loaded mesenchymal stem cells has been used in several 
animal models (14-18). However, the animal models used to date limit the study of pro-
inflammatory status of MSCs after OAdv infection and its effect on tumor growth. On one hand, 
immunodeficient mice bearing human xenograft tumors lack a complete immune system and 
pro-inflammatory responses. On the other hand, human adenoviruses show species-specific 
replication, thus limiting the study of oncolysis and antitumor immune responses in 
immunocompetent mice.  
We have recently described the advantages of using menstrual blood-derived mesenchymal stem 
cells (MenSCs) as an alternative to bone-marrow mesenchymal stem cells as cell carriers for 
OAdv (19). In this follow-up study, we sought to assess the antitumor efficacy of OAdv infected 
human menstrual blood-derived mesenchymal stem cells in the presence of autologous and 
allogeneic human peripheral blood mononuclear cells (PBMCs). We show that infection by 
OAdv induces MenSCs immunophenotypic profile changes, generating a pro-inflammatory 
environment in co-cultures with allogeneic PBMCs, mainly mediated by monocyte activation, 
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and resulting in the activation of both T-cells and Natural Killer cells (NK cells). Finally, we 
demonstrate that combination of allogeneic PBMCs and OAdv-loaded MenSCs present an 
enhanced antitumor efficacy both in vitro and in vivo, with monocytes and NK cells playing an 
important role in this efficacy.  
 
MATERIALS AND METHODS 
Cell culture 
The cancer cell lines A549 (human lung adenocarcinoma), A431 (epidermoid carcinoma), FaDu 
(pharynx squamous cell carcinoma) and HEK-293 (human embryonic kidney) were obtained and 
authenticated by STR profiling by the American Type Culture Collection (ATCC, Manassas, 
VA). All tumor cell lines were maintained with Dulbecco’s Modified Eagle’s Medium 
supplemented with 5 or 10% fetal bovine serum and 1% penicillin/streptomycin (Life 
Technologies, Carlsbad, CA, USA) at 37ºC, 5% CO2. Cell lines were routinely tested for 
mycoplasma presence. The A431-GL and FaDu-GL cell line was generated by sorting of A431 
and FaDu cells previously transduced with a lentiviral vector encoding GFP and luciferase. 
Isolation and characterization of MenSCs has been previously described (19). Although different 
MenSCs passages were used through the different experiments (based on sample availability), 
the same cell passage from different donors was always used for each experiment, being 5 the 
highest passage used. 
All experiments employing human PBMCs were approved by the ethics committees of the 
University Hospital of Bellvitge and the Blood and Tissue Bank (BST) from Catalonia. PBMCs 
of healthy donors were isolated from the blood by ficoll (Rafer, Spain) density gradient 
centrifugation in Leucosep tubes (Greiner Bio-one, Kremsmünster, Austria) following 
manufacturer’s recommendations. NK- or monocyte-depleted PBMCs were generated using 
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human CD56 or CD14 microbeads respectively, LD columns and MidiMACS separator (all from 
MiltenyiBiotec, BergischGladbach, Germany).  
Oncolytic adenovirus 
The oncolytic adenovirus used though this work has been ICOVIR15, previously described by 
our group (20). 
Flow cytometry analysis of Toll-like receptor 9  
MenSCs (1x10
5
cells/sample) from 3 different donors (passage 3) were infected with ICOVIR15 
at 50 TU/cell. After 24h, cells were analyzed by flow cytometry for expression of TLR-9. 
Allophycocyanin (APC)-conjugated antibody against TLR9 (Thermo Fisher Scientific, Waltham, 
MA USA, clone eB72-1665) was used. A Gallios cytometer (Beckman Coulter, Brea, CA, USA) 
was used and 10,000 events were analyzed for each sample. FlowJo v7.6.5 (Tree Star, Inc., San 
Carlos, CA, USA) software was used for the analysis of the data.  
NF-B reporter luciferase assay 
1x10
5
MenSCs (passage 2) were transduced for 16h with the non-replicative lentiviral vector 
pHAGE-NFkB-TA-LUC-UBS-GFP-W (kindly provided by Dr. García-Castro, Addgene plasmid 
#49343) at a multiplicity of infection (MOI) of 2. This lentiviral vector encodes the NF-kB 
consensus binding sequence upstream of the minimal TA promoter of herpes simplex virus 
followed by the firefly luciferase and GFP genes under the control of the ubiquitin-C promoter. 
Transduced MenSCs were infected with ICOVIR15 at 50 TU/cell, and luciferase activity from 
cell lysis was determined at different time-points post-infection using the luciferase assay system 
(Promega Corporation, Madison, WI, USA). 
Cytokine array and Luminex quantification 
1x10
6
MenSCs (passage 3) were infected with ICOVIR15 at 50 TU/cell in duplicate. After 48h, 
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the supernatant from infected or uninfected MenSCs was collected and the secreted cytokine 
profile was evaluated using two different analysis: the Proteome Profiler Human Cytokine Array 
Kit (R&D; Minneapolis, MN, USA) and the Th1/Th2/Th9/Th17/Th22/Treg Cytokine 18-Plex 
Human ProcartaPlex Panel (Thermo Fisher Scientific). For the former, cytokine quantification 
was determined by estimating the spot integrated density using the ImageLab software (Bio-Rad 
Laboratories, Hercules, CA, USA). For the Cytokine Array using the multiplexing unit MAGPIX 
(Luminex Corporation, Austin, TX, USA) and the ProcartaPlex Analyst software (Thermo Fisher 
Scientific) for the ProcartaPlex Panel. 
Enzyme-linked immunosorbent assay (ELISA) 
MenSCs (2.5x10
5 
cells per well in 6-well plaques) from 3 different donors (passage 3) were 
infected with ICOVIR15 at an MOI of 50 for 24h. The next day, PBMCs from the same donors 
or from an allogeneic donor were isolated using ficoll gradient centrifugation. Autologous or 
allogeneic PBMCs (2.5x10
6 
PBMCs) were co-cultured with infected or uninfected MenSCs 
(PBMCs:MenSCs = 10). After 48h of incubation, co-culture supernatants were collected and 
cytokine level was assessed with the human IFN-γ, TNF-α (Peprotech, Rocky Hill, NJ, USA), 
IL-2 (Biolegend) or IFN- (Mabtech AB, Nacka Strand Sweden) ELISA kits according to the 
manufacturer’s instructions.  
Flow cytometry analysis of PBMCs cell activation.  
For the T-cells and NK cells activation assay, MenSCs from 3 different donors (passage 4) were 
infected with ICOVIR15 at a MOI of 50 for 24h. The next day, PBMCs from autologous and one 
allogeneic donor were isolated and co-cultured directly in contact or using a transwell system 
with infected or un-infected MenSCs (PBMCs-to-MenSCs ration of 10) in triplicate. After 48h 
of co-culture, PBMCs were harvested, stained for cell viability with LIVE/DEAD 
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Green  (Thermo Fisher Scientific), divided into two different samples followed by incubation 
with: panel 1 (T-cell activation) and panel 2 (NK cell activation) (see supplementary Material 
and Methods for antibodies details). A Gallios cytometer was used and 20,000 live lymphocytes 
were analyzed for each sample.  
In vitro cytotoxicity assay 
MenSCs (passage 4) were infected with ICOVIR15 at MOI 50 for 24h. The next day, PBMCs 
from an allogeneic donor were isolated using ficoll gradient centrifugation. Infected or 
uninfected MenSCs, allogeneic PBMCs and tumoral cells expressing GFP protein (A431-GL or 
FaDu-GL) were co-cultured in 24-well plates at the following cell density (in triplicates): 


















when A431-GL or FaDu-GL were present respectively). After 5 days in co-culture, viable GFP-
expressing tumoral cells were determined by flow cytometry (negative for LIVE/DEAD and 
positive for GFP). CountBright absolute counting beads (Thermo Fisher Scientific) were used for 
absolute cell number determination. Cytotoxicity was expressed as the percentage of live cancer 
cells in co-cultures normalized to that of cancer cells cultured alone. 
In vivo oncolytic adenovirus tumor delivery and antitumor efficacy 
In vivo studies were performed at the ICO-IDIBELL animal facility (Barcelona, Spain) 
AAALAC unit 1155, and approved by IDIBELL’s Ethical Committee for Animal 
Experimentation.  
Athymic nu/nu mice 
Lung adenocarcinoma xenograft tumors were established by implanting 5×10
6
 A549 cells 
subcutaneously into both flanks of 8-week-old female Athymic nu/nu mice. When tumors 
reached 100-120 mm
3
, mice were randomized and distributed into groups. To evaluate systemic 
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efficacy, animals were treated with a single intraperitoneal dose of PBS or 5×10
10
vp/mice of 
OAdv (ICOVIR15), MenSCs (4x10
6
 cells) or MenSC/OAdv (4x10
6
 cells previously infected 
with ICOVIR15 at MOI 50 for 24h).  
NOD scid gamma (NSG) mice 
The same tumor model was established but in this case implanting 5×10
6
 A549 or A431 cells 
suspended in a 100μL PBS and Matrigel mixture (1:1, v/v; BD biosciences) into both flanks of 
8-week-old NSG mice. When tumors reached 100-120 mm
3
, mice were randomized and 
distributed into the following groups: allogeneic PBMCs + PBS; MenSCs; OAdv or 
MenSCs/OAdv (MenSCs previously infected with ICOVIR15 at MOI 50 for 24h) and 
MenSCs/OAdv without allogeneic PBMCs (only for the A549 experiment). To evaluate 
antitumor efficacy, 1x10
7
 human allogeneic PBMCs were administered to the mice by 
intravenous injection except animals receiving only MenSCs/OAdv. The next day, animals were 
treated with a single intraperitoneal dose of PBS, 1×10
10





 MenSCs/OAdv.  




×L, where W and L 
are the width and the length of the tumor, respectively. Data are expressed as the tumor size 
relative to the size at the beginning of the therapy (tumor growth). At the end of the study, 
animals were euthanized and tumors were collected. One half was frozen for DNA extraction, 
and the other half was fixed in 4% formaldehyde for 24h and embedded in paraffin. 
For the antitumor efficacy studies involving monocytes and NK cell-depleted allogeneic 
PBMCs, the same animal and tumor model were used. When A549 tumors reached 100-120 
mm
3
, mice were randomized and distributed into the following groups: allogeneic PBMCs + 
PBS or MenSCs/OAdv, allogeneic PBMCs depleted for monocytes + MenSCs/OAdv and 
allogeneic PBMCs depleted for NK cells + MenSCs/OAdv. PBMCs from a single donor were 
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isolated, and a part of the sample was depleted for monocytes or NK cells as described above. 
Monocytes and NK-depletion was confirmed by flow cytometry after staining of the cells with 
LIVE/DEAD violet, and APC-CD14 or PE-CD56. Finally, 1x10
7 
human allogeneic PBMCs, 
human allogeneic monocytes-depleted PBMCs or human allogeneic NK-depleted PBMCs were 
administered to the mice by intravenous injection. Next day, animals were treated with a single 
intraperitoneal dose of PBS or 5x10
6
 MenSCs/OAd and tumor size was monitored as previously 
described. 
Determination of adenoviral genomes in tumor samples 
A549 frozen tumor samples were mechanically homogenized and total DNA was extracted 
following the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) protocol for tissue DNA 
Purification.  Adenoviral genome copies were quantified in triplicate by Quantitative Real Time-
PCR using the specific set of primers targeting the hexon sequence (forward 5’-CTT CGA TGA 
TGC CGC AGT G-3', reverse 5'-ATG AAC CGC AGC GTC AAA CG-3’). PCR conditions 
were: 95°C 10 minutes, 40x cycles of 95°C 15 seconds, 60°C 1 minute and 72°C 7 seconds. Real 
Time PCR was performed using LightCycler 480 SYBR Green I Master (Roche). Adenoviral 
genome copy numbers were calculated using a standard curve of serially diluted pAd5wt, a 
plasmid containing the complete Adenoviral type 5 genome and for which the genome copy 
number was known. 
Histology and immunohistochemistry  
A549 paraffin-embedded sections (5-m thickness) of tumors samples were treated with an anti-
Ad2/5E1A antibody (SC-430, Santa Cruz, Dallas, TX, USA) as primary antibody diluted 1/200 
in PBS. Immunohistochemical staining was performed with EnVision (DAKO, Hamburg, 
Germany), according to manufactures’ instructions, and with hematoxylin and eosin. Images 
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were acquired using the Nikon Eclipse 80i microscope running NIS elements BR software 
(Nikon Instruments Europe BV, Amsterdam, Netherlands). 
Statistical analysis 
Statistical comparisons between two groups were performed using the Mann-Whitney U test (2-
tailed). For comparison of more than two groups, Kruskal-Wallis with Dunn post-hoc test was 
used. Statistical significance was established as p<0.05. Data are presented as the mean ±SD or 
SEM. All statistical analysis were calculated with GraphPad Prism software. 
 
RESULTS 
Immunophenotypic profile changes in MenSCs after OAdv infection  
Adenoviral infection has been described as triggering the expression of TLR-9 in different cell 
types (21,22). We therefore decided to evaluate the expression of TLR9 on MenSCs in response 
to OAdv infection. 24h after OAdv infection, the percentage of MenSCs expressing TLR9 was 
significantly increased 1.46-fold (Figure 1A). We next studied the activation of NF-B pathway 
in MenSCs after OAdv infection. For this, MenSCs were transduced with a lentiviral vector 
containing a NF-B promoter-driven luciferase reporter system for detecting NF-B activation 
(23), and luciferase expression was evaluated at different time points after OAdv infection. 
Significant expression of luciferase was observed 24h post-infection (Figure 1B), indicating an 
activation of the NF-B pathway after OAdv infection.  
To determine whether OAdv-induced NF-B activation triggers the expression of immune 
response genes, we evaluated the production of several pro-inflammatory and immune-related 
cytokines in uninfected or OAdv-infected MenSCs after 48h of infection using both, a cytokine 
array and a Luminex assay. From the 36 cytokines quantified in the cytokine array 
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(supplementary Fig.1), only macrophage migration inhibitory factor (MIF), IL-8 and Serpin 
E1could be detected, and all three were overexpressed after OAd infection (fold-increase of 1.79, 
2.27 and 9.01, respectively) (Figure 1C). Results from the 19 cytokines evaluated with the 
Luminex assay confirmed the overexpression of IL-8 (fold-increase of 1.29), and revealed a 
slight increase in the expression of IL-9, IL-18 and IL-21 after virus infection (Figure 1D). 
By knocking down the TLR-9 expression on MenSCs using a lentivirus coding for a short 
hairpin-RNA against the human TLR-9, we confirmed the role of the receptor on the NF-B 
pathway activation and cytokines expression after OAdv infection (supplementary figure 2).  
In summary, these results indicate an increase in the secretion profile of specific pro-
inflammatory cytokines in response to the NF-B pathway activation in MenSCs after OAdv 
infection, as a result the activation of TLR-9 by viral genome.  
 
OAdv infected MenSCs stimulate a pro-inflammatory environment in co-culture with 
allogeneic PBMCs. 
To evaluate if OAdv-loaded MenSCs have an effect on the immunological status of PBMCs, we 
first analyzed the expression of several pro-inflammatory cytokines from autologous or 
allogeneic human PBMCs co-cultured with uninfected or OAdv-infected MenSCs for 48h. 
Uninfected MenSCs, independently from the source of the PBMCs, and infected MenSCs in co-
culture with autologous PBMCs had no significant effect on the secretion of cytokines by 
PBMCs (Figure 2). However, a significant increase in the expression level of all four cytokines 
evaluated was observed when human allogeneic PBMCs were co-cultured in the presence of 
OAd-infected MenSCs, indicating the induction of a pro-inflammatory environment in the co-
culture. In order to determine the contribution of different cell subtypes in the induction of this 
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pro-inflammatory environment, infected or uninfected MenSCs were cultured in the presence of 
allogeneic PBMCs from which monocytes, NK cells, or both were previously depleted. We 
found that the depletion of monocytes in the co-culture significantly decreased the level of all 
four cytokines indicating their importance in establishing the pro-inflammatory environment 
(Figure 3). 
To evaluate if this pro-inflammatory environment triggers the activation of the different cell 





 T cells and NK cells in co-culture with infected or uninfected MenSCs. As shown in 
Fig.4A, pro-inflammatory cytokines secreted by the co-culture of human allogeneic PBMCs and 




T-cell activation as indicated by an increase in 
the expression of the activation markers CD69 in both cell lines, and CD25 in CD4
+ 
T-cell in 
response not only to the presence of the virus but also in the use of allogeneic PBMCs. Similarly, 




) expressing the activation marker CD69 
was significantly higher when allogeneic PBMCs were co-cultured with OAd-infected MenSCs 
(Figure 4B). Moreover, the percentage and intensity of NK cells expressing the degranulation 
marker CD107a was significantly higher when OAd-infected MenSCs were co-cultured not only 
with allogeneic but also with autologous PBMCs, probably indicating the effect of the OAdv on 
NK activation. To confirm that secreted factors from OAdv-infected MenSCs induce the 
observed T-cells and NK-cell activation, a similar experiment was carried out but including a 
transwell assay to separate PBMCs from infected MenSCs. Thus, CD69 upregulation was 








cells employing direct contact cell-to-
cell or transwell co-culture assays. As shown in figure 4C, whereas a similar and significant 
CD69 upregulation was detected for all cell types evaluated independently of the co-culture 
conditions (direct cell-to-cell contact or using transwells), no differences where determined 
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between the co-culture methodology used. This result points out the role of the soluble factor 
secreted by OAdv-secreted MenSCs on cell activation. 
Overall these finding demonstrate that co-culture of allogeneic PBMCs and OAdv-loaded 
MenSCs induce a pro-inflammatory environment mediated in part by monocytes, which results 




T-cell and NK cells.  
 
Allogeneic PBMCs enhance the antitumor efficacy of OAdv-loaded MenSCs in vitro. 
We next addressed if allogeneic PBMCs could increase the antitumor efficacy of OAdv-infected 
MenSCs in vitro. For this, two different GFP-expressing cancer cell lines (A431-GL and FaDu-
GL, both of them considered partly resistant to adenovirus infection) were co-cultured with 
OAdv-infected or uninfected MenSCs in the presence or absence of allogeneic PBMCs for 5 
days, and the percentage of cancer cell death was determined by flow cytometry. The 
combination of allogeneic PBMCs and OAdv loaded MenSCs showed increased antitumor 
efficacy compared to OAdv-infected MenSCs alone or uninfected MenSCs in combination with 
allogeneic PBMCs (Figure 5). 
 
Allogeneic human PBMCs increase the antitumor efficacy of OAdv-loaded MenSCs in vivo 
We recently reported the tumor homing properties of MenSCs/OAdv after systemic 
administration in human tumor-bearing athymic nu/nu mice (19), but the antitumor efficacy of 
this strategy was not evaluated. We therefore evaluated the antitumor efficacy of OAdv-loaded 
MenSCs in A549-tumor bearing nude mice. In contrast to the treatment with OAd alone, in 
which tumor growth was significantly controlled, OAdv-loaded MenSCs showed only moderate 
antitumor efficacy (Figure 6A). These results suggest that although MenSCs migrated to the 
tumors after systemic administration, the amount of cells arriving at and the number of virus 
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particles delivered to the tumors during the first days after treatment was not enough to control 
tumor growth. Nevertheless, the total viral genomes detected in tumors at the end of the 
experiment were similar to the OAdv group. This apparently contradiction could be explained 
considering that the OAdv content in tumor at early stages of the experiment determines the 
antitumor efficacy at later stages. Thus, directly administrated OAdv leads to a larger amount of 
initial virus in the tumor that is able to control tumor growth but also depletes the substrate 
(tumor cells) faster. Tumors develop fibroblast barriers, which do not allow the efficient spread 
of the virus, and these barriers form isolated tumor nodules that eventually grow without virus. 
At the end of the experiments the tumors analyzed contained few virus despite their lower size. 
However, for the MenSCs/OAdv group, since the initial amount of virus in the tumor is lower, 
the scarce amount of foci of replicating virus cannot eliminate all the tumor cells in these fast-
growing tumor models and there is no apparent antitumor efficacy but as the permissive 
substrate (tumor cells) is not eliminated, the virus is amplified progressively until the end of the 
experiment. . 
Since the above-described in vitro characterization strongly suggests an important role of 
MenSC/OAdv in modulating the antitumor immune response of allogeneic PBMCs, we 
hypothesized that the in vivo antitumor efficacy of MenSC/OAdv could be improved in the 
presence of human immune cells. We decided to use the immunodeficient mouse model NSG 
with human tumors and human PBMCs, a model previously used to evaluate the combination of 
human adenovirus and human PBMCs (24,25).  
Thus, NSG mice bearing subcutaneous A549 tumors received an intravenous injection of 10
7 
human allogeneic PBMCs. The next day, mice received a single intraperitoneal injection of PBS, 
OAdv (ICOVIR15), MenSCs or MenSC/OAdv. A group consisting of mice treated with 
MenSC/OAdv in the absence of human allogeneic PBMCs was also included to specifically 
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evaluate the effect of the human allogeneic PBMCs on the MenSC/OAdv antitumor activity. To 
simplify the experiment, and taking into account our previous result where human PBMCs had 
no effect on tumor growth (24), we did not evaluate the rest of the groups in the absence of 
human PBMCs. As shown in figure 6B, antitumor efficacy could be detected only when OAdv-
loaded MenSCs were combined with the administration of allogeneic PBMCs, pointing out the 
relevance of allogeneic PBMCs in the antitumor effect. Importantly, there were no differences in 
the viral load in the tumors at the end of the experiment among MenSCs OAdv-loaded groups in 
the presence or absence of human allogeneic PBMCs, indicating that PBMCs did not interfere 
with MenSCs/OAdv tumor homing. A visual not quantitative analysis of diverse IHC images 
from each group was performed to confirm the presence of OAdv in the tumors. Histology of the 
tumors at the end of the experiment revealed the expression of the E1a protein in tumors of 
animals treated with the oncolytic adenovirus alone or in combination with MenSCs, confirming 
the correct OAdv delivery and amplification in tumors. We also tested the antitumor efficacy of 
the different groups in the presence of human allogeneic PBMCs in a second tumor model, NSG 
mice bearing subcutaneously A431 tumors and transferred with human PBMCs. As show in the 
figure 6C, a significant tumor growth control was observed only for the MenSCs/OAdv treated 
group, although it was restricted to early days after treatment (from day 3 to day 8). However, 
this result is of special interest since A431 are partly resistant to adenovirus infection strongly 
suggesting the effect of the allogeneic PBMCs on the efficacy observed since low or no viral 
replication is expected in this tumoral cells. 
 




Finally, having demonstrated the importance of monocytes in establishing the pro-inflammatory 
environment, and the NK cell activation in vitro after allogeneic PBMCs and OAdv-loaded 
MenSCs co-culture, we next evaluated the influence of these cell types on the antitumor efficacy 
observed in vivo. NSG mice bearing subcutaneous A549 tumors received an intravenous 
injection of 10
7 
human allogeneic PBMCs, 10
7 





NK-depleted human allogeneic PBMCs (PBMCs-NK
-
). 24h later, mice 
received a single intraperitoneally administration of PBS or 5x10
6 
MenSCs/OAdv. As show in 
the figure 6D, a significant tumor growth control was observed only when a complete PBMCs 
administration was done. These differences were significant against both, the monocyte and NK 
cell depleted groups, although it was restricted to early days after treatment (from day 3 to day 
8). Nevertheless, at the end of the experiment the group transferred with fully PBMCs showed 
1.5 and 1.6-fold decrease ((p=0.066 and 0.057) in the percentage of tumor growth compared to 
groups depleted for NK cells and monocytes respectively. We consider that these results support 
the hypothesis of the role of the innate response on the tumor control efficacy observed for 
OAdv-loaded MenSCs treatment. 
 
DISCUSSION 
In the present work we evaluated the effect of OAd infection on MenSCs at the level of their 
immune profile, their behavior in the presence of autologous or allogeneic human PBMCs, and 
their impact in antitumor efficacy in vitro and in vivo. We show that adenovirus infection of 
MenSCs increases the expression of TLR-9, leading to NF-B pathway activation. We also 
detected an increase in the expression of diverse proinflammatory cytokines, including 
macrophage migration inhibitory factor, an upstream activator of innate immunity (26), IL-8, a 
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proinflammatory cytokine also overexpressed in MSCs after TLR-3 and TLR-4 stimulation (27), 
and Serpin E1, which stimulates macrophage activation through TLR signaling (28), among 
others. These results are in agreement with studies evaluating adenovirus infection of dendritic 
cells showing that, during endosomal trafficking, Ad5 virions are accumulated in the late 
endosomal compartment where they are fused with vesicles carrying TLR-9 (22). This receptor 
recognizes unmethylated CpG motifs in the adenovirus double-stranded DNA), leading to 
transcriptional activation of pro-inflammatory cytokine and inflammasome-related genes via 
NFB and AP-1 signaling pathways (29,30). Moreover, taking into account the multiple 
mechanisms used by mesenchymal stem cells to modulate the immune system, we cannot 
discard additional immunophenotypic changes on MenSCs after OAdv infection than those 
evaluated in this work. Altogether our results confirm that adenovirus infection alters the 
immune status of MenSCs towards a more proinflammatory profile, as a result of OAd-mediated 
stimulation of TLR-9, as described for other MSCs’ TLR stimulation (9). 
We further evaluated the effect of this adenovirus-specific MenSCs immune profile on the 
activation of the immune system in vitro. A clear pro-inflammatory environment was detected 
when infected MenSCs were co-cultured with allogeneic, but not with autologous, PBMCs. Pro-
inflammatory cytokines were highly expressed (IFN-, TNF-, IL-2, and IFN-) in these co-
culture conditions, mainly mediated by monocyte activation and probably in response to the 
presence of adenovirus as previously described (31,32). Interestingly, this pro-inflammatory 
environment was, in part, independent of cell contact but related to soluble factors secreted by 





activation as indicated by an increase in the expression of CD69 and CD25, in response not only 
to the presence of the virus but also to the HLA mismatch between the CD4
+ 
T-cell and MenSCs. 
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Different studies have recently pointed out the capacity of oncolytic virotherapy to promote 
intratumoral T-cell infiltration and enhance checkpoint inhibitor immunotherapy (33,34), 
therefore it is plausible to expect a similar effect for OAdv-infected MenSCs. NK cell activation 
was also detected when infected MenSCs were co-cultured with allogeneic PBMCs as shown by 
the expression of CD69 and CD107a. These results are in agreement with a previous study in 
which oncolytic reovirus infection stimulate monocytes to secrete IFN-α, resulting in NK cell 
activation and improved antitumor efficacy (35).  
A greater antitumor potency of OAd-loaded MenSCs and allogeneic PBMCs combination was 
confirmed not only in vitro (evaluated in FaDu and A431cell lines, partly resistant to adenovirus 
infection (36,37)), but most importantly in vivo. In this work, we demonstrate for the first time 
the antitumor efficacy of OAdv-loaded MSCs after only a single systemic administration, 
indicating that this antitumor efficacy is mediated by the presence of allogeneic PBMCs. 
Moreover, when NK cells are depleted from PBMCs transferred to mice, antitumor efficacy is 
lost, indicating the important role of NK cells in the antitumor efficacy exerted by OAdv-loaded 
MSCs. A similar lack of antitumor efficacy was observed with monocyte-depleted PBMCs as 
expected according to the role described for monocytes on NK cell activation (38,39) and our 
own in vitro results. Finally, it is worth mentioning the limitation of our model in which only 
innate immune responses can be studied since no adaptive responses are generated in this mouse 
model. Thus, this model is likely underestimating the overall antitumor efficacy since recent 
evidence suggest that NK cells can act as initiators of adaptive immune response (reviewed in 
(40)). 
In summary, our work describes the immune-stimulatory properties of allogeneic MenSCs 
infected with oncolytic adenoviruses and their potential benefits as an alternative to the 
conventional autologous MSCs used in the CELYVIR clinical trials. In this regard, the clinical 
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benefits using OAdv-infected allogeneic MSCs to treat canine tumors also support the use of 
healthy allogeneic donor MSCs instead of autologous MSCs (5). Interestingly, in this study there 
was no correlation between the gender of the MSCs donor or patient and the efficacy observed, 
indicating that OAdv-loaded MSCs could be a potential treatment not only for female but also 
for male patients. Thus, to create a homogenous and well characterized allogeneic MSCs master 
bank from allogeneic healthy donors, should be considered for the future development of 
CELYVIR. MenSCs have been extensively characterized in vitro and in vivo and their potential 
for cellular therapy has been described (41-43), pointing out that menstrual blood represents an 
efficient and ethically accepted source of MSCs, and could be considered to generate this MSCs 
master bank. Finally, data accumulated from patients, dogs and preclinical assays (including the 
present work) strongly suggest the role of the immune system status in the outcome of the 
therapy. Although a specific predictive marker has still not been found, assessing the patient 
immune system and the capability of OAd-loaded MSCs from different donors to activate 
patients PBMCs could serve as a biomarker for therapy outcome. 
From here on, another important factor in improving the efficacy of CELYVIR should be the 
optimization of the oncolytic adenovirus used by, for example, using more potent oncolytic 
adenoviruses (44) or oncolytic adenoviruses encoding immunostimulatory sequences or 
transgenes to enhance the immune response against the tumor (24,45,46).   
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Figures and legends 
Figure 1. Effect of oncolytic adenovirus infection on MenSCs immunophenotypic profile. 
(A) MenSCs expressing TLR-9 was analyzed by flow cytometry on OAdv-infected (white) or 
uninfected (black) MenSCs. Bars represent the mean ± SD of triplicates from three independent 
experiments. *, P< 0.05 by Mann-Whitney test. (B) Luciferase activity was determined from 
OAdv infected or uninfected MenSCs/pHAGE-NFB-GFP/Luc cell lysates at different time-
points after infection. Bars represent the mean ± SD of triplicates from three independent 
experiments. *, P< 0.05 by Mann-Whitney test. The supernatants from uninfected or 48h OAdv-
infected MenSCs were analysed for the presence of secreted cytokines. (C) Pixel intensity 
quantification is shown after Proteome Profiler Human Cytokine Array analysis. IL-8, 
interleukin 8; MIF, Macrophage migration inhibitory factor. Bars represent the mean ± SD of 
spot duplicates from two independent experiments. (D) Luminex analysis of cytokine 
concentration is shown. Bars represent the mean ± SD of duplicates from two independent 
experiments. 
 
Figure 2. Pro-inflammatory cytokines production in autologous or allogeneic PBMCs co-
cultures with OAdv-infected MenSCs. Uninfected or OAdv-infected (MOI = 50) MenSCs 
from 3 different donors were co-cultured with autologous or allogeneic human PBMCs at a 
PBMCs-to-MenSCs ratio of 10 in triplicates. After 48h of co-culture, culture medium was 
collected and cytokines level assessed by ELISA. The mean ± SD of triplicates from two 





Figure 3. Effect of monocyte and/or NK cell depletion on pro-inflammatory cytokines 
production in co-cultures of OAdv-MenSCs and allogeneic PBMCs. Allogeneic human 
PBMCs from the same donor were depleted for monocytes and/or NK cells, and co-cultured  
with uninfected or OAdv-infected MenSCs (PBMCs:MenSC =10). Non-depleted PBMCs alone 
or in co-culture with OAdv-infected MenSCs were used as control. After 48h of co-culture, 
culture medium was collected and cytokines level assessed by ELISA. The mean ± SD of 
triplicates from two independent experiments is shown. *, P< 0.05; **, P< 0.01; ***, P< 0.001 






 T-cell and NK-cell activation in co-cultures of autologous or 
allogeneic human PBMCs with OAdv-infected MenSCs. Uninfected or OAdv-infected 
MenSCs were co-cultured with autologous or allogeneic human PBMCs at a PBMCs-to-MenSCs 
ratio of 10 in triplicates. After 48h of co-culture, PBMCs were harvested and T cells and NK 
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positive cells expressing CD69 is represented.The mean ± SD of triplicates from two 
independent experiments is shown in all analysis. *, P< 0.05; **, P< 0.01, ***, P<0.001 by 
Kruskal-Wallis with Dunn post-hoc test. 
 
Figure 5. Antitumor efficacy of OAdv-loaded MenSCs in vitro. A431-GL and FaDu-GL 
cancer cell lines were co-cultured with OAdv-infected or un-infected MenSCs in the presence or 
absence of allogeneic PBMCs (PBMCs:cancer cell ratio = 10) in triplicates. After 5 days in co-
culture, live cancer cells were counted by flow cytometer. Cytotoxicity was expressed as the 
percentage of live cancer cells on co-cultures, normalized to the number of cancer cells cultured 
alone. *, P< 0.05; by Kruskal-Wallis with Dunn post-hoc test. Results from two independent 
experiments is shown. 
 
Figure 6. Antitumor efficacy of OAdv-loaded MenSCs in vivo. (A) Athymic nu/nu mice 
bearing subcutaneous A549 tumors were intraperitoneally injected with PBS, MenSCs, OAdv or 
MenSCs previously infected with OAdv (n=7 mice per group). Left, the mean of tumor growth ± 
SEM is shown. *, P< 0.05, **, P< 0.01, ***, P<0.001 OAdv versus PBS group; #, P< 0.05 OAdv 
versus MenSCs; &, P< 0.05 OAdv versus MenSCs/OAdv group by Kruskal-Wallis with Dunn 
post-hoc test. Right, the presence of OAdv genomes in tumors at the end of the experiment was 
assessed by real-time PCR. (B) NSG mice bearing subcutaneous A549 tumors received an 
intravenous injection of human allogeneic PBMCs except one group (n=7 mice per group). Next 
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day, mice were intraperitoneally injected with PBS, MenSCs, OAdv or MenSCs previously 
infected with OAdv. Left, the mean of tumor growth ± SEM is shown. *, P< 0.05, **, P< 0.01 
allogeneic PBMCs+MenSC/OAdv versus PBS group by Kruskal-Wallis with Dunn post-hoc test. 
Right, the presence of OAdv genomes in tumors at the end of the experiment was assessed by 
real-time. Bottom panel, immunohistochemical staining of E1A of a representative tumor from 
each group is shown. The arrow points to positive virus E1A staining. (C) NSG mice bearing 
subcutaneous A431 tumors were treated as previously described. The mean of tumor growth ± 
SEM is shown. *, P< 0.05, **, P< 0.01 allogeneic PBMCs+MenSC/OAdv versus PBS group; #, 
P< 0.05 allogeneic PBMCs+MenSC/OAdv versus MenSCs; &, P< 0.05, allogeneic 
PBMCs+MenSC/OAdv versus OAdv group, by Kruskal-Wallis with Dunn post-hoc test. (D) 
NSG mice bearing subcutaneous A549 tumors received an intravenous injection of human 
allogeneic PBMCs or PBMCs previously depleted for monocytes or NK cells (n=7 mice per 
group). Next day, mice were intraperitoneally injected with PBS, or MenSCs previously infected 
with OAdv. Right, the mean of tumor growth ± SEM is shown. #, P< 0.05, allogeneic 
PBMCs+MenSC/OAdv versus allogeneic PBMCs-NK
-
+MenSC/OAdv group; &, P< 0.05, 
allogeneic PBMCs+MenSC/OAdv versus allogeneic PBMCs-Mo
-
+MenSC/OAdv group by 
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SUPPLEMENTARTY MATERIALS AND METHODS 
Flow cytometry analysis of PBMC activation.  
Panel 1 (T-cell activation): PE-CD4 (Biolegend, clone OKT4), V500-CD8 (BD 
Biosciences, San Jose, CA, USA, clone RPA-T8), APC-CD25 (Biolegend, clone BC96), 
and Pe-Cy7-CD69 (BD Biosciences, clone FN5U). Panel 2 (NK cell activation) PE-CD56 
(BD Biosciences, clone B159); V500-CD16 (BD Biosciences, clone 3G8) Pe-Cy7-CD69 
(BD Biosciences, clone FN5U), and BV421-CD107a (BD Biosciences, clone H4A3) 
antibodies for flow cytometer quantification. The corresponding fluorescent, isotype-
matched negative control antibodies defined the background staining. 
RNA interference  
A lentivirus vector harboring a shRNA expression cassette against human TLR-9 (LV-
shTLR9) was kindly provided by Dr. Kremmer (13). MenSCs from 3 different donors 
(passage 3) and MenSCs/pHAGE-NFkB-GFPLuc were transduced with LV-shTLR9. 
shRNA knockdown efficacy was confirmed by Quantitative Real Time-PCR (qRT-PCR). 
Gene-expression analysis by RT-PCR 
Quantitative RT-PCR was used to analyze TLR-9, MIF, IL-8, and Serpin E1 expression. 
RNA from frozen OAd-infected or uninfected MenSCs and MenSCs/pHAGE-NFkB-
GFPLuc cell pellets was extracted with a DNA/RNA/Protein extraction kit (IBI 
Scientific, Peosta, IA, USA), and treated with Turbo DNA-free (Thermo Scientific) to 
remove genomic DNA. RNA (g) was reverse transcribed with the PrimeScript RT 
reagent kit (Takara Bio, Shiga, Japan), according to the manufacturer's instructions. qRT-
PCR was performed using the LightCycler 480  SYBR Green I Master (Roche, Basel, 
Switzerland) in a LightCycler® 480 II machine (Roche) and analyzed with the 
LightCycler® 480 Software release 1.5.0 SP4 (Roche). The following primers were used: 
TLR9F: 5′-CCGTGACAATTACCTGGCCTTC-3 and TLR9R: 5′-
CAGGGCCTTCAGCTGGTTTC-3′ for human TLR-9; MIFF: 5’-
CGCAGAACCGCTCCTACAG-3’ and MIFR:5’-GGAGTTGTTCCAGCCCACAT-3’ 
for human MIF; IL8F: 5’-TTTTGCCAAGGAGTGCTAAAGA-3’ and IL8R: 5’–
AACCCTCTGCACCCAGTTTTC-3’ for human IL-8; SerpinE1F: 5’-
TCAAAACACAACTTCTCAGTGTCATC-3’ and SerpinE1R: 5’-
AGCTTGCAACATACCAGATATTGC-3’; and B-ActinF: 5´-
CTGGAACGGTGAAGGTGACA-3` and B-ActinR: 5’-
GGGAGAGGACTGGGCCATT-3’ for human -Actin. PCR conditions were: an 
activation cycle (95ºC, 10minutes) followed by 40 amplification cycles (95ºC 15 seconds, 
60ºC 1 minute and 72ºC 7 seconds). Target gene expression was calculated by the 





Supplementary Figure 1. Cytokine array. Proteome Profiler Human Cytokine Array 
Kit. (A) A direct visualization of spots is shown. RS, reference spots; IL-8, interleukin 8; 









Supplementary Figure 2. Effect of TLR-9 knock-down on OAd-infected MenSCs 
properties. (A) qRT-PCR to detect relative expression of TLR-9 from three different 
MenSCs donors, untreated or infected with a lentivirus conding for a small hairpin-RNA 
against the human TLR-9. The mean ± SD from two independent experiments is shown. 
***, P< 0.001 by Mann-Whitney test. (B) Luciferase activity from normal or TLR-9 
down-regulated MenSCs±OAdv cell lysates was determined 48h after infection. Whereas 
a significant increase of luminescence signal was detected when MenSCs/pHAGE-
NFKB-GFPLuc were infected with the OAdv, the signal coming from MenSCs/pHAGE-
NFKB-GFPLuc treated with the LV-shTLR-9 did not change after OAdv infection. Bars 
represent the mean ± SD of triplicates from two independent experiments. *, P< 0.05 by 
Mann-Whitney test. (C) qRT-PCR to detect the relative expression of MIF, Serpin E1, 
and IL-8 from three different MenSCs donors, untreated or infected with a lentivirus 
conding for a small hairpin-RNA against the human TLR-9. A reduction in the relative 
transcript levels of MIF, Serpin E1, and IL-8 were observed in OAd-infected MenSCs 
after TLR-9 down-regulation. The mean ± SD from two independent experiments is 
shown. **, P< 0.01 by Mann-Whitney test. 
 
 
